Fig. 5: ISL1 enhances gastric cancer tumorigenesis through ZEB1. | Cell Death & Disease

Fig. 5: ISL1 enhances gastric cancer tumorigenesis through ZEB1.

From: ISL1 predicts poor outcomes for patients with gastric cancer and drives tumor progression through binding to the ZEB1 promoter together with SETD7

Fig. 5

a Pie diagram summarizing the genomic occupancy of ISL1-bound regions as revealed by ChIP-seq. b GO functional clustering of upregulated genes allowed the identification of cellular functions directly regulated by ISL1. c Genome-wide analysis of downstream targets of ISL1. Overlap of RNA-seq and ChIP-seq results revealed 1039 genes as potential direct targets of ISL1. d Western blotting analysis of ZEB1 and EMT-associated proteins. e The mRNA expression of ISL1 and ZEB1 was analyzed by real-time RT-PCR in 36 paired GC samples with GAPDH as the reference gene. f GEPIA results indicated a correlation between ISL1 and ZEB1 gene expression in stomach adenocarcinoma samples from the TCGA. g Kaplan–Meier survival curves of survival time for patients with high vs. normal ZEB1 expression. ISL1 expression was assessed in 36 paired human GC tissues (P = 0.0196). h Kaplan–Meier survival reanalysis of overall survival. The data were obtained from publicly available gene expression datasets (GSE14210, GSE15459, GSE22377, GSE29272, GSE51105)

Back to article page